Edition:
United States

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

6.60USD
16 Feb 2018
Change (% chg)

$0.63 (+10.55%)
Prev Close
$5.97
Open
$6.09
Day's High
$6.62
Day's Low
$6.05
Volume
268,529
Avg. Vol
160,681
52-wk High
$15.51
52-wk Low
$5.02

Latest Key Developments (Source: Significant Developments)

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas
Tuesday, 15 Aug 2017 04:46pm EDT 

Aug 15 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum Pharmaceuticals says ‍on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas .Bellicum Pharmaceuticals- under agreement CPRIT awarded grant of about $16.9 million to bellicum to fund research of a cancer therapy involving BPX-501​.Bellicum Pharmaceuticals Inc - Bellicum and CPRIT will retain joint ownership over any intellectual property developed under agreement.Bellicum Pharmaceuticals Inc - agreement will expire on February 29, 2020.  Full Article

Bellicum Pharmaceuticals qtrly loss per share $0.74
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Bellicum pharmaceuticals inc qtrly loss per share $0.74.Bellicum pharmaceuticals inc says enrollment in pivotal eu bp-004 trial remains on track for completion by end of 2017.Bellicum pharmaceuticals -expects to initiate observational trial in pediatric patients receiving transplants from matched unrelated donors without bpx-501 in q3.  Full Article

Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln
Wednesday, 28 Jun 2017 05:26pm EDT 

June 28 (Reuters) - Bellicum Pharmaceuticals Inc -:Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing.  Full Article

Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares
Wednesday, 28 Jun 2017 04:58pm EDT 

June 28 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares of co's common stock held by the selling stockholders.Bellicum Pharmaceuticals says it is not selling any shares of common stock and will not receive any of the proceeds from sale of shares by selling stockholders.  Full Article

Bellicum Pharmaceuticals qtrly loss per share $0.80
Monday, 8 May 2017 04:05pm EDT 

May 8 (Reuters) - Bellicum Pharmaceuticals Inc :Bellicum pharmaceuticals reports first quarter 2017 financial results.Bellicum pharmaceuticals inc - qtrly loss per share $0.80.Q1 earnings per share view $-0.70 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum Pharmaceuticals says public offering of 5 mln shares priced at $12 each
Thursday, 23 Mar 2017 08:49pm EDT 

Bellicum Pharmaceuticals Inc : Bellicum Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.00 million common shares priced at $12.00per share.  Full Article

Bellicum Pharmaceuticals says public offering of 5 mln shares priced at $12 each
Thursday, 23 Mar 2017 06:20pm EDT 

Bellicum Pharmaceuticals Inc : Bellicum Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.00 million common shares priced at $12.00per share.  Full Article

Bellicum Pharmaceuticals announces proposed public offering of 5 mln common stock
Wednesday, 22 Mar 2017 04:01pm EDT 

Bellicum Pharmaceuticals Inc : Bellicum Pharmaceuticals announces proposed public offering of common stock .Says offering 5.00 million common shares.  Full Article

Bellicum Pharmaceuticals posts Q4 net loss $19.9 mln
Monday, 13 Mar 2017 04:05pm EDT 

Bellicum Pharmaceuticals Inc : Bellicum Pharmaceuticals provides operational update and reports financial results for the fourth quarter and year ended December 31, 2016 . Bellicum Pharmaceuticals Inc - Bellicum ended year on December 31, 2016 with cash, restricted cash and investments totaling $113.4 million . Bellicum Pharmaceuticals Inc - expects that current cash resources will be sufficient to meet operating requirements through at least Q1 of 2018 . Bellicum Pharma- projected cash outlays in 2017 include about $15 million for capital projects, primarily completion of buildout of in-house facilities .Bellicum Pharmaceuticals Inc - reported a net loss of $19.9 million for Q4 of 2016.  Full Article

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.